ALDH1A2

Across TCGA pan-cancer cohorts, ALDH1A2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ALDH1A2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ALDH1A2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ALDH1A2 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where ALDH1A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALDH1A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.456	<.001	12	view →
LSCC	Female	All	−1.752	<.001	9	view →
LUAD	Female	III,IV	−1.292	<.001	9	view →
HNSC	Male	III,IV	−1.392	<.001	8	view →
PDAC	Female	All	−1.041	<.001	6	view →
OV	All	All	−2.076	<.001	2	view →
COAD	All	All	−1.008	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ALDH1A2–CCRCC

Open the CCRCC breakdown →